Guselkumab improvements for psoriatic arthritis persist ... | 合法藥品大搜索

由 A Deodhar 著作 · 2018 · 被引用 121 次 — Guselkumab, a novel anti-interleukin 23p19 antibody, significantly improved signs and symptoms of active psoriatic arthritis and was well ... Read More

TREMFYA® (guselkumab) is approved for the treatment of active psoriatic arthritis (PsA) in adults. See full Prescribing & Safety Information. Read More

由 PJ Mease 著作 · 被引用 1 次 — In this NMA, guselkumab demonstrated favorable arthritis efficacy comparable to IL-17A and subcutaneous TNF inhibitors while offering better ... Read More

由 A Deodhar 著作 · 2020 · 被引用 70 次 — Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an ... Read More

由 A Deodhar 著作 · 2018 · 被引用 121 次 — Interpretation: Guselkumab, a novel anti-interleukin 23p19 antibody, significantly improved signs and symptoms of active psoriatic arthritis and ... Read More

由 PJ Mease 著作 · 2021 · 被引用 1 次 — Guselkumab is a monoclonal antibody currently approved for the treatment of psoriasis and also for psoriatic arthritis in some regions [8]. Guselkumab offers a ... Read More

2020年7月16日 — Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) ... Read More

2020年7月14日 — Guselkumab Approved for Psoriatic Arthritis ... The U.S. Food and Drug Administration has approved the first IL-23 inhibitor for moderate to severe ... Read More

2021年4月26日 — ... his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Read More

2020年10月15日 — Guselkumab improvements for psoriatic arthritis persist through 1 year ... Adults with active psoriatic arthritis (PsA) treated with guselkumab ( ... Read More